Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Colorectal Neoplasms

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 365 articles:
HTML format

Single Articles

    September 2020
  1. YOO E, Lee J, Lertpatipanpong P, Ryu J, et al
    Anti-proliferative activity of A. Oxyphylla and its bioactive constituent nootkatone in colorectal cancer cells.
    BMC Cancer. 2020;20:881.
    PubMed     Abstract available

  2. DAVIS JS, Kanikarla-Marie P, Gagea M, Yu PL, et al
    Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development.
    BMC Cancer. 2020;20:871.
    PubMed     Abstract available

  3. COEBERGH VAN DEN BRAAK RRJ, Ten Hoorn S, Sieuwerts AM, Tuynman JB, et al
    Interconnectivity between molecular subtypes and tumor stage in colorectal cancer.
    BMC Cancer. 2020;20:850.
    PubMed     Abstract available

  4. OKUYAMA T, Sameshima S, Takeshita E, Mitsui T, et al
    Myxoid stroma is associated with postoperative relapse in patients with stage II colon cancer.
    BMC Cancer. 2020;20:842.
    PubMed     Abstract available

  5. AL-KHAYAL K, Vaali-Mohammed MA, Elwatidy M, Traiki TB, et al
    Correction to: A novel coordination complex of platinum (PT) induces cell death in colorectal cancer by altering redox balance and modulating MAPK pathway.
    BMC Cancer. 2020;20:834.
    PubMed     Abstract available

    August 2020
  6. DAMATO A, Iachetta F, Antonuzzo L, Nasti G, et al
    Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    BMC Cancer. 2020;20:822.
    PubMed     Abstract available

  7. TABUNG FK, Noonan A, Lee DH, Song M, et al
    Post-diagnosis dietary insulinemic potential and survival outcomes among colorectal cancer patients.
    BMC Cancer. 2020;20:817.
    PubMed     Abstract available

  8. SCHRAA SJ, van Rooijen KL, van der Kruijssen DEW, Rubio Alarcon C, et al
    Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    BMC Cancer. 2020;20:790.
    PubMed     Abstract available

  9. VAN DEN BERG I, van de Weerd S, Roodhart JML, Vink GR, et al
    Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study.
    BMC Cancer. 2020;20:776.
    PubMed     Abstract available

  10. BAQAR AR, Wilkins S, Wang W, Oliva K, et al
    Log odds of positive lymph nodes is prognostically equivalent to lymph node ratio in non-metastatic colon cancer.
    BMC Cancer. 2020;20:762.
    PubMed     Abstract available

    July 2020
  11. EL ASRI A, Zarrouq B, El Kinany K, Bouguenouch L, et al
    Associations between nutritional factors and KRAS mutations in colorectal cancer: a systematic review.
    BMC Cancer. 2020;20:696.
    PubMed     Abstract available

  12. ONWUKA JU, Li D, Liu Y, Huang H, et al
    A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility.
    BMC Cancer. 2020;20:692.
    PubMed     Abstract available

  13. MIYO M, Kato T, Yoshino T, Yamanaka T, et al
    Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
    BMC Cancer. 2020;20:687.
    PubMed     Abstract available

  14. AL-KHAYAL K, Vaali-Mohammed MA, Elwatidy M, Bin Traiki T, et al
    A novel coordination complex of platinum (PT) induces cell death in colorectal cancer by altering redox balance and modulating MAPK pathway.
    BMC Cancer. 2020;20:685.
    PubMed     Abstract available

  15. ANTONIOTTI C, Borelli B, Rossini D, Pietrantonio F, et al
    AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    BMC Cancer. 2020;20:683.
    PubMed     Abstract available

  16. YANG SY, Kim MJ, Kye BH, Han YD, et al
    Prospective study of oncologic outcomes after laparoscopic modified complete mesocolic excision for non-metastatic right colon cancer (PIONEER study): study protocol of a multicentre single-arm trial.
    BMC Cancer. 2020;20:657.
    PubMed     Abstract available

  17. LIN JL, Lin JX, Zheng CH, Li P, et al
    Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
    BMC Cancer. 2020;20:638.
    PubMed     Abstract available

  18. RUHNAU J, Parczyk J, Danker K, Eickholt B, et al
    Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism.
    BMC Cancer. 2020;20:617.
    PubMed     Abstract available

  19. GUTIERREZ-STAMPA MA, Aguilar V, Sarasqueta C, Cubiella J, et al
    Impact of the faecal immunochemical test on colorectal cancer survival.
    BMC Cancer. 2020;20:616.
    PubMed     Abstract available

    June 2020
  20. ALTUNEL E, Roghani RS, Chen KY, Kim SY, et al
    Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.
    BMC Cancer. 2020;20:592.
    PubMed     Abstract available

  21. YANG X, Wu W, Pan Y, Zhou Q, et al
    Immune-related genes in tumor-specific CD4(+) and CD8(+) T cells in colon cancer.
    BMC Cancer. 2020;20:585.
    PubMed     Abstract available

  22. PARAKRAMA R, Fogel E, Chandy C, Augustine T, et al
    Immune characterization of metastatic colorectal cancer patients post reovirus administration.
    BMC Cancer. 2020;20:569.
    PubMed     Abstract available

  23. NEGARANDEH R, Salehifar E, Saghafi F, Jalali H, et al
    Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients.
    BMC Cancer. 2020;20:560.
    PubMed     Abstract available

  24. PENG Q, Shen Y, Zhao P, Cheng M, et al
    Biomarker roles identification of miR-106 family for predicting the risk and poor survival of colorectal cancer.
    BMC Cancer. 2020;20:506.
    PubMed     Abstract available

    May 2020
  25. BUCKSCH K, Zachariae S, Aretz S, Buttner R, et al
    Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.
    BMC Cancer. 2020;20:460.
    PubMed     Abstract available

  26. SUN Y, Cao B, Zhou J
    Roles of DANCR/microRNA-518a-3p/MDMA ceRNA network in the growth and malignant behaviors of colon cancer cells.
    BMC Cancer. 2020;20:434.
    PubMed     Abstract available

  27. EYL RE, Thong MSY, Carr PR, Jansen L, et al
    Physical activity and long-term fatigue among colorectal cancer survivors - a population-based prospective study.
    BMC Cancer. 2020;20:438.
    PubMed     Abstract available

  28. DAVIDSEN J, Jessen SB, Watt SK, Larsen S, et al
    CDX2 expression and perioperative patient serum affects the adhesion properties of cultured colon cancer cells.
    BMC Cancer. 2020;20:426.
    PubMed     Abstract available

  29. SALIMZADEH H, Lindskog EB, Gustavsson B, Wettergren Y, et al
    Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    BMC Cancer. 2020;20:409.
    PubMed     Abstract available

  30. CHEN H, Luo J, Guo J
    Development and validation of a five-immune gene prognostic risk model in colon cancer.
    BMC Cancer. 2020;20:395.
    PubMed     Abstract available

  31. CALCATERRA SL, Burnett-Hartman AN, Powers JD, Corley DA, et al
    A population-based survey to assess the association between cannabis and quality of life among colorectal cancer survivors.
    BMC Cancer. 2020;20:373.
    PubMed     Abstract available

  32. PARK JH, Lee DH, Kim SI, Kim NK, et al
    Moderate to vigorous physical activity participation associated with better quality of life among breast and colorectal cancer survivors in Korea.
    BMC Cancer. 2020;20:365.
    PubMed     Abstract available

    April 2020
  33. WU P, Zhou Q, Zhu H, Zhuang Y, et al
    Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon.
    BMC Cancer. 2020;20:354.
    PubMed     Abstract available

  34. KITAGAWA Y, Osumi H, Shinozaki E, Ota Y, et al
    Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective stud
    BMC Cancer. 2020;20:358.
    PubMed     Abstract available

  35. ERFANI M, Hosseini SV, Mokhtari M, Zamani M, et al
    Altered ARID1A expression in colorectal cancer.
    BMC Cancer. 2020;20:350.
    PubMed     Abstract available

  36. THERKILDSEN C, Rasmussen M, Smith-Hansen L, Kallemose T, et al
    Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort.
    BMC Cancer. 2020;20:345.
    PubMed     Abstract available

  37. EL DIN KS, Loree JM, Sayre EC, Gill S, et al
    Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review.
    BMC Cancer. 2020;20:288.
    PubMed     Abstract available

  38. ORJUELA S, Menigatti M, Schraml P, Kambakamba P, et al
    The DNA hypermethylation phenotype of colorectal cancer liver metastases resembles that of the primary colorectal cancers.
    BMC Cancer. 2020;20:290.
    PubMed     Abstract available

    March 2020
  39. KOSARI F, Taheri M, Moradi A, Hakimi Alni R, et al
    Evaluation of cinnamon extract effects on clbB gene expression and biofilm formation in Escherichia coli strains isolated from colon cancer patients.
    BMC Cancer. 2020;20:267.
    PubMed     Abstract available

  40. SCHLIEMANN D, Paramasivam D, Dahlui M, Cardwell CR, et al
    Change in public awareness of colorectal cancer symptoms following the Be Cancer Alert Campaign in the multi-ethnic population of Malaysia.
    BMC Cancer. 2020;20:252.
    PubMed     Abstract available

  41. SIEBENHUNER AR, Guller U, Warschkow R
    Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases.
    BMC Cancer. 2020;20:246.
    PubMed     Abstract available

  42. ZHOU F, Tang D, Xu Y, He H, et al
    Identification of microRNAs and their Endonucleolytic Cleavaged target mRNAs in colorectal cancer.
    BMC Cancer. 2020;20:242.
    PubMed     Abstract available

  43. JIN XH, Lu S, Wang AF
    Expression and clinical significance of miR-4516 and miR-21-5p in serum of patients with colorectal cancer.
    BMC Cancer. 2020;20:241.
    PubMed     Abstract available

  44. LYHNE JD, Smith A'B, Frostholm L, Fink P, et al
    Study protocol: a randomized controlled trial comparing the efficacy of therapist guided internet-delivered cognitive therapy (TG-iConquerFear) with augmented treatment as usual in reducing fear of cancer recurrence in Danish colorectal cancer survivo
    BMC Cancer. 2020;20:223.
    PubMed     Abstract available

  45. LI J, Xu X, Jiang Y, Hansbro NG, et al
    Elastin is a key factor of tumor development in colorectal cancer.
    BMC Cancer. 2020;20:217.
    PubMed     Abstract available

    February 2020
  46. XU R, Wang W, Zhu B, Lin X, et al
    Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China.
    BMC Cancer. 2020;20:131.
    PubMed     Abstract available

  47. MIELE E, Abballe L, Spinelli GP, Besharat ZM, et al
    BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.
    BMC Cancer. 2020;20:129.
    PubMed     Abstract available

  48. SHEN Y, Guan Y, Hummel JJ, Shyu CR, et al
    Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer.
    BMC Cancer. 2020;20:124.
    PubMed     Abstract available

  49. PERROTT S, Laurie K, Laws K, Johnes A, et al
    Young-onset colorectal cancer in the North East of Scotland: survival, clinico-pathological features and genetics.
    BMC Cancer. 2020;20:108.
    PubMed     Abstract available

  50. CHEN F, Qu M, Zhang F, Tan Z, et al
    IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?
    BMC Cancer. 2020;20:92.
    PubMed     Abstract available

  51. IVESON T, Carter AM, Shiu KK, Spooner C, et al
    Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
    BMC Cancer. 2020;20:91.
    PubMed     Abstract available

    January 2020
  52. MANOHARAN V, Karunanayake EH, Tennekoon KH, De Silva S, et al
    Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
    BMC Cancer. 2020;20:72.
    PubMed     Abstract available

  53. HAN JG, Wang ZJ, Zeng WG, Wang YB, et al
    Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer.
    BMC Cancer. 2020;20:57.
    PubMed     Abstract available

  54. NOH BJ, Kwak JY, Eom DW
    Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    BMC Cancer. 2020;20:58.
    PubMed     Abstract available

  55. FOWLER H, Belot A, Ellis L, Maringe C, et al
    Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers.
    BMC Cancer. 2020;20:2.
    PubMed     Abstract available

  56. SIGNAL V, Jackson C, Signal L, Hardie C, et al
    Improving management of comorbidity in patients with colorectal cancer using comprehensive medical assessment: a pilot study.
    BMC Cancer. 2020;20:50.
    PubMed     Abstract available

  57. KOHOUTOVA D, Forstlova M, Moravkova P, Cyrany J, et al
    Bacteriocin production by mucosal bacteria in current and previous colorectal neoplasia.
    BMC Cancer. 2020;20:39.
    PubMed     Abstract available

  58. WANG Q, Wang Z, Wu Y, Klinke DJ 2nd, et al
    An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer.
    BMC Cancer. 2020;20:26.
    PubMed     Abstract available

  59. KAWAMURA H, Morishima T, Sato A, Honda M, et al
    Effect of adjuvant chemotherapy on survival benefit in stage III colon cancer patients stratified by age: a Japanese real-world cohort study.
    BMC Cancer. 2020;20:19.
    PubMed     Abstract available

  60. QADERI SM, Wijffels NAT, Bremers AJA, de Wilt JHW, et al
    Major differences in follow-up practice of patients with colorectal cancer; results of a national survey in the Netherlands.
    BMC Cancer. 2020;20:22.
    PubMed     Abstract available

    December 2019
  61. WANG X, Yu Q, Ghareeb WM, Zhang Y, et al
    Downregulated SPINK4 is associated with poor survival in colorectal cancer.
    BMC Cancer. 2019;19:1258.
    PubMed     Abstract available

  62. ZHANG X, Sun H, Chen W, He X, et al
    Elevated expression of AGGF1 predicts poor prognosis and promotes the metastasis of colorectal cancer.
    BMC Cancer. 2019;19:1252.
    PubMed     Abstract available

  63. KOTANI D, Kuboki Y, Horasawa S, Kaneko A, et al
    Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    BMC Cancer. 2019;19:1253.
    PubMed     Abstract available

  64. SASTRE D, Baiochi J, de Souza Lima IM, Canto de Souza F, et al
    Focused screening reveals functional effects of microRNAs differentially expressed in colorectal cancer.
    BMC Cancer. 2019;19:1239.
    PubMed     Abstract available

  65. SONG N, Lee J, Cho S, Kim J, et al
    Evaluation of gene-environment interactions for colorectal cancer susceptibility loci using case-only and case-control designs.
    BMC Cancer. 2019;19:1231.
    PubMed     Abstract available

  66. ZHANG X, Browman G, Siu W, Basen-Engquist KM, et al
    The BE GONE trial study protocol: a randomized crossover dietary intervention of dry beans targeting the gut microbiome of overweight and obese patients with a history of colorectal polyps or cancer.
    BMC Cancer. 2019;19:1233.
    PubMed     Abstract available

  67. LIU X, Fu J, Bi H, Ge A, et al
    DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients.
    BMC Cancer. 2019;19:1212.
    PubMed     Abstract available

  68. JANG YC, Huang HL, Leung CY
    Association of hormone replacement therapy with mortality in colorectal cancer survivor: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:1199.
    PubMed     Abstract available

  69. SHANG L, Fang Z, Liu J, Du F, et al
    Case report of ascending colon cancer and multiple jejunal GISTs in a patient with neurofibromatosis type 1 (NF1).
    BMC Cancer. 2019;19:1196.
    PubMed     Abstract available

  70. MANCEAU G, Brouquet A, Chaibi P, Passot G, et al
    Multicenter phase III randomized trial comparing laparoscopy and laparotomy for colon cancer surgery in patients older than 75 years: the CELL study, a Federation de Recherche en Chirurgie (FRENCH) trial.
    BMC Cancer. 2019;19:1185.
    PubMed     Abstract available

  71. WEBER S, Koschade SE, Hoffmann CM, Dubash TD, et al
    The notch target gene HEYL modulates metastasis forming capacity of colorectal cancer patient-derived spheroid cells in vivo.
    BMC Cancer. 2019;19:1181.
    PubMed     Abstract available

    November 2019
  72. PURCELL RV, Schmeier S, Lau YC, Pearson JF, et al
    Molecular subtyping improves prognostication of Stage 2 colorectal cancer.
    BMC Cancer. 2019;19:1155.
    PubMed     Abstract available

  73. GARCIA-GARCIA T, Carmona-Bayonas A, Jimenez-Fonseca P, Jara C, et al
    Biopsychosocial and clinical characteristics in patients with resected breast and colon cancer at the beginning and end of adjuvant treatment.
    BMC Cancer. 2019;19:1143.
    PubMed     Abstract available

  74. WANG HE, Liao YC, Hu JM, Wu WC, et al
    Correlation between kidney transplantation and colorectal cancer in hemodialysis patients: A nationwide, retrospective, population-based cohort study.
    BMC Cancer. 2019;19:1120.
    PubMed     Abstract available

  75. CALAPRE L, Warburton L, Millward M, Gray ES, et al
    Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report.
    BMC Cancer. 2019;19:1109.
    PubMed     Abstract available

  76. XU Y, Xu Q, Ma Y, Duan J, et al
    Characterizing MRI features of rectal cancers with different KRAS status.
    BMC Cancer. 2019;19:1111.
    PubMed     Abstract available

  77. MUSSELWHITE LW, Redding TS 4th, Sims KJ, O'Leary MC, et al
    Advanced neoplasia in Veterans at screening colonoscopy using the National Cancer Institute Risk Assessment Tool.
    BMC Cancer. 2019;19:1097.
    PubMed     Abstract available

  78. LI JB, Luo S, Wong MCS, Li C, et al
    Longitudinal associations between BMI change and the risks of colorectal cancer incidence, cancer-relate and all-cause mortality among 81,388 older adults : BMI change and the risks of colorectal cancer incidence and mortality.
    BMC Cancer. 2019;19:1082.
    PubMed     Abstract available

  79. SHENG H, Wei X, Mao M, He J, et al
    Adenocarcinoma with mixed subtypes is a rare but aggressive histologic subtype in colorectal cancer.
    BMC Cancer. 2019;19:1071.
    PubMed     Abstract available

  80. KALMAR A, Nagy ZB, Galamb O, Csabai I, et al
    Genome-wide expression profiling in colorectal cancer focusing on lncRNAs in the adenoma-carcinoma transition.
    BMC Cancer. 2019;19:1059.
    PubMed     Abstract available

  81. AHIKO Y, Shida D, Horie T, Tanabe T, et al
    Controlling nutritional status (CONUT) score as a preoperative risk assessment index for older patients with colorectal cancer.
    BMC Cancer. 2019;19:946.
    PubMed     Abstract available

  82. STRICKLER JH, Rushing CN, Niedzwiecki D, McLeod A, et al
    A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
    BMC Cancer. 2019;19:1032.
    PubMed     Abstract available

  83. MARTIN SZ, Wagner DC, Horner N, Horst D, et al
    Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer.
    BMC Cancer. 2019;19:1030.
    PubMed     Abstract available

  84. TROTSYUK I, Sparschuh H, Muller AJ, Neumann K, et al
    Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy.
    BMC Cancer. 2019;19:1033.
    PubMed     Abstract available

    October 2019
  85. LI J, Kong XX, Zhou JJ, Song YM, et al
    Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: a multicenter, open-label randomized controlled study.
    BMC Cancer. 2019;19:988.
    PubMed     Abstract available

  86. JOHANSEN AFB, Kassentoft CG, Knudsen M, Laursen MB, et al
    Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
    BMC Cancer. 2019;19:971.
    PubMed     Abstract available

  87. ADVANI SM, Advani PS, Brown DW, DeSantis SM, et al
    Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.
    BMC Cancer. 2019;19:964.
    PubMed     Abstract available

  88. LI C, He X, Zhang L, Li L, et al
    A pair-wise meta-analysis highlights circular RNAs as potential biomarkers for colorectal cancer.
    BMC Cancer. 2019;19:957.
    PubMed     Abstract available

  89. YE SB, Cheng YK, Zhang L, Wang XP, et al
    Prognostic value of estrogen receptor-alpha and progesterone receptor in curatively resected colorectal cancer: a retrospective analysis with independent validations.
    BMC Cancer. 2019;19:933.
    PubMed     Abstract available

    September 2019
  90. MIZUSHIMA T, Ikeda M, Kato T, Ikeda A, et al
    Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.
    BMC Cancer. 2019;19:929.
    PubMed     Abstract available

  91. SAVOIE MB, Laffan A, Brickman C, Daniels B, et al
    A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer.
    BMC Cancer. 2019;19:906.
    PubMed     Abstract available

  92. OTTAIANO A, Scala S, Normanno N, Napolitano M, et al
    Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.
    BMC Cancer. 2019;19:899.
    PubMed     Abstract available

  93. HAGHI F, Goli E, Mirzaei B, Zeighami H, et al
    The association between fecal enterotoxigenic B. fragilis with colorectal cancer.
    BMC Cancer. 2019;19:879.
    PubMed     Abstract available

  94. CONRADI LC, Spitzner M, Metzger AL, Kisly M, et al
    Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.
    BMC Cancer. 2019;19:880.
    PubMed     Abstract available

    August 2019
  95. AL-HUSSEINI MJ, Saad AM, Mohamed HH, Alkhayat MA, et al
    Impact of prior malignancies on outcome of colorectal cancer; revisiting clinical trial eligibility criteria.
    BMC Cancer. 2019;19:863.
    PubMed     Abstract available

  96. LI M, Olver I, Keefe D, Holden C, et al
    Pre-diagnostic colonoscopies reduce cancer mortality - results from linked population-based data in South Australia.
    BMC Cancer. 2019;19:856.
    PubMed     Abstract available

  97. ANTOUN S, Bayar MA, Dyevre V, Lanoy E, et al
    No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.
    BMC Cancer. 2019;19:847.
    PubMed     Abstract available

  98. LAWRANCE S, Bui C, Mahindra V, Arcorace M, et al
    Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
    BMC Cancer. 2019;19:850.
    PubMed     Abstract available

  99. YOU Q, Fang Y, Li C, Tan Y, et al
    Multiple metastases of bones and sigmoid colon after mastectomy for ductal carcinoma in situ of the breast: a case report.
    BMC Cancer. 2019;19:844.
    PubMed     Abstract available

  100. WAN N, Weinberg D, Liu TY, Niehaus K, et al
    Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA.
    BMC Cancer. 2019;19:832.
    PubMed     Abstract available

  101. LI H, Jin X, Liu B, Zhang P, et al
    CircRNA CBL.11 suppresses cell proliferation by sponging miR-6778-5p in colorectal cancer.
    BMC Cancer. 2019;19:826.
    PubMed     Abstract available

  102. PERILLI L, Tessarollo S, Albertoni L, Curtarello M, et al
    Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer.
    BMC Cancer. 2019;19:821.
    PubMed     Abstract available

  103. XIE X, Yin J, Zhou Z, Dang C, et al
    Young age increases the risk for lymph node metastasis in patients with early Colon Cancer.
    BMC Cancer. 2019;19:803.
    PubMed     Abstract available

  104. TANAKA T, Sato T, Nishiofuku H, Masada T, et al
    Selective TACE with irinotecan-loaded 40 mum microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.
    BMC Cancer. 2019;19:758.
    PubMed     Abstract available

    July 2019
  105. IMAIZUMI J, Shida D, Narita Y, Miyakita Y, et al
    Prognostic factors of brain metastases from colorectal cancer.
    BMC Cancer. 2019;19:755.
    PubMed     Abstract available

  106. DAPPER H, Schiller K, Munch S, Peeken JC, et al
    Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines.
    BMC Cancer. 2019;19:742.
    PubMed     Abstract available

  107. SARASQUETA C, Perales A, Escobar A, Bare M, et al
    Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage III colon or stage II/III rectal cancer.
    BMC Cancer. 2019;19:735.
    PubMed     Abstract available

  108. FERNANDEZ-BANARES F, Cleries R, Boadas J, Ribes J, et al
    Prediction of advanced colonic neoplasm in symptomatic patients: a scoring system to prioritize colonoscopy (COLONOFIT study).
    BMC Cancer. 2019;19:734.
    PubMed     Abstract available

  109. TANABE T, Shida D, Komukai S, Nakamura Y, et al
    Long-term outcomes after surgical dissection of inguinal lymph node metastasis from rectal or anal canal adenocarcinoma.
    BMC Cancer. 2019;19:733.
    PubMed     Abstract available

  110. CHAKROBORTY D, Emani MR, Klen R, Bockelman C, et al
    L1TD1 - a prognostic marker for colon cancer.
    BMC Cancer. 2019;19:727.
    PubMed     Abstract available

  111. GEMOLL T, Miroll E, Klein O, Lischka A, et al
    Spatial UBE2N protein expression indicates genomic instability in colorectal cancers.
    BMC Cancer. 2019;19:710.
    PubMed     Abstract available

  112. GUAN X, Ma CX, Quan JC, Li S, et al
    A clinical model to predict the risk of synchronous bone metastasis in newly diagnosed colorectal cancer: a population-based study.
    BMC Cancer. 2019;19:704.
    PubMed     Abstract available

  113. BENCSIKOVA B, Budinska E, Selingerova I, Pilatova K, et al
    Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
    BMC Cancer. 2019;19:687.
    PubMed     Abstract available

  114. GAO Y, Nan X, Shi X, Mu X, et al
    SREBP1 promotes the invasion of colorectal cancer accompanied upregulation of MMP7 expression and NF-kappaB pathway activation.
    BMC Cancer. 2019;19:685.
    PubMed     Abstract available

  115. ALWERS E, Blaker H, Walter V, Jansen L, et al
    External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS.
    BMC Cancer. 2019;19:681.
    PubMed     Abstract available

  116. DUDANI S, Marginean H, Tang PA, Monzon JG, et al
    Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.
    BMC Cancer. 2019;19:664.
    PubMed     Abstract available

  117. ADLARD KN, Jenkins DG, Salisbury CE, Bolam KA, et al
    Peer support for the maintenance of physical activity and health in cancer survivors: the PEER trial - a study protocol of a randomised controlled trial.
    BMC Cancer. 2019;19:656.
    PubMed     Abstract available

  118. NG TH, Sham KWY, Xie CM, Ng SSM, et al
    Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer.
    BMC Cancer. 2019;19:649.
    PubMed     Abstract available

    June 2019
  119. CAVAGNARI MAV, Silva TD, Pereira MAH, Sauer LJ, et al
    Impact of genetic mutations and nutritional status on the survival of patients with colorectal cancer.
    BMC Cancer. 2019;19:644.
    PubMed     Abstract available

  120. CHEN SH, Tsai HL, Jiang JK, Sung YC, et al
    Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol.
    BMC Cancer. 2019;19:640.
    PubMed     Abstract available

  121. PETERSEN CH, Mahmood B, Badsted C, Dahlby T, et al
    Possible predisposition for colorectal carcinogenesis due to altered gene expressions in normal appearing mucosa from patients with colorectal neoplasia.
    BMC Cancer. 2019;19:643.
    PubMed     Abstract available

  122. TERAZAWA T, Kato T, Goto M, Sakai D, et al
    First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602.
    BMC Cancer. 2019;19:623.
    PubMed     Abstract available

  123. SONG Z, Chen E, Qian J, Xu J, et al
    Serum chitinase activity prognosticates metastasis of colorectal cancer.
    BMC Cancer. 2019;19:629.
    PubMed     Abstract available

  124. JIANG Y, Sun Y, Hu J, Yu N, et al
    A germline mutation in Rab43 gene identified from a cancer family predisposes to a hereditary liver-colon cancer syndrome.
    BMC Cancer. 2019;19:613.
    PubMed     Abstract available

  125. WANG H, Wang X, Xu L, Zhang J, et al
    Analysis of the transcriptomic features of microsatellite instability subtype colon cancer.
    BMC Cancer. 2019;19:605.
    PubMed     Abstract available

  126. FENG Y, Qian W, Zhang Y, Peng W, et al
    CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo.
    BMC Cancer. 2019;19:576.
    PubMed     Abstract available

  127. CALLEBOUT E, Ribeiro SM, Laurent S, De Man M, et al
    Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    BMC Cancer. 2019;19:567.
    PubMed     Abstract available

  128. LEKOANE KMB, Kuupiel D, Mashamba-Thompson TP, Ginindza TG, et al
    Evidence on the prevalence, incidence, mortality and trends of human papilloma virus-associated cancers in sub-Saharan Africa: systematic scoping review.
    BMC Cancer. 2019;19:563.
    PubMed     Abstract available

  129. VRINTEN C, Gallagher A, Waller J, Marlow LAV, et al
    Cancer stigma and cancer screening attendance: a population based survey in England.
    BMC Cancer. 2019;19:566.
    PubMed     Abstract available

  130. CARRATO A, Benavides M, Massuti B, Ferreiro-Monteagudo R, et al
    First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
    BMC Cancer. 2019;19:533.
    PubMed     Abstract available

  131. SAIJO S, Kuwano Y, Tange S, Rokutan K, et al
    A novel long non-coding RNA from the HOXA6-HOXA5 locus facilitates colon cancer cell growth.
    BMC Cancer. 2019;19:532.
    PubMed     Abstract available

  132. TSAOUSIS GN, Papadopoulou E, Apessos A, Agiannitopoulos K, et al
    Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
    BMC Cancer. 2019;19:535.
    PubMed     Abstract available

    May 2019
  133. ROQUETTE R, Painho M, Nunes B
    Geographical patterns of the incidence and mortality of colorectal cancer in mainland Portugal municipalities (2007-2011).
    BMC Cancer. 2019;19:512.
    PubMed     Abstract available

  134. CHEN Y, Yang X, Wen Z, Liu Y, et al
    Association between high-resolution MRI-detected extramural vascular invasion and tumour microcirculation estimated by dynamic contrast-enhanced MRI in rectal cancer: preliminary results.
    BMC Cancer. 2019;19:498.
    PubMed     Abstract available

  135. ABRAHAMSSON H, Porojnicu AC, Lindstrom JC, Dueland S, et al
    High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer.
    BMC Cancer. 2019;19:488.
    PubMed     Abstract available

  136. KIM EG, Kim JO, Park HS, Ryu CS, et al
    Genetic associations between the miRNA polymorphisms miR-130b (rs373001), miR-200b (rs7549819), and miR-495 (rs2281611) and colorectal cancer susceptibility.
    BMC Cancer. 2019;19:480.
    PubMed     Abstract available

  137. WANG F, He MM, Wang ZX, Li S, et al
    Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer.
    BMC Cancer. 2019;19:460.
    PubMed     Abstract available

  138. BURM R, Thewes B, Rodwell L, Kievit W, et al
    Long-term efficacy and cost-effectiveness of blended cognitive behavior therapy for high fear of recurrence in breast, prostate and colorectal Cancer survivors: follow-up of the SWORD randomized controlled trial.
    BMC Cancer. 2019;19:462.
    PubMed     Abstract available

  139. CHEN Z, Wu G, Ye F, Chen G, et al
    High expression of MMP19 is associated with poor prognosis in patients with colorectal cancer.
    BMC Cancer. 2019;19:448.
    PubMed     Abstract available

  140. SUN J, Fei F, Zhang M, Li Y, et al
    The role of (m)SEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer.
    BMC Cancer. 2019;19:450.
    PubMed     Abstract available

  141. PENNEY ME, Parfrey PS, Savas S, Yilmaz YE, et al
    Correction to: A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer.
    BMC Cancer. 2019;19:437.
    PubMed     Abstract available

  142. NAKAGAWA-SENDA H, Hori M, Matsuda T, Ito H, et al
    Prognostic impact of tumor location in colon cancer: the Monitoring of Cancer Incidence in Japan (MCIJ) project.
    BMC Cancer. 2019;19:431.
    PubMed     Abstract available

  143. PRIETO SP, Reed CL, James HM, Quinn KP, et al
    Differences in colonic crypt morphology of spontaneous and colitis-associated murine models via second harmonic generation imaging to quantify colon cancer development.
    BMC Cancer. 2019;19:428.
    PubMed     Abstract available

  144. HENDRICKS A, Gieseler F, Nazzal S, Brasen JH, et al
    Prognostic relevance of topoisomerase II alpha and minichromosome maintenance protein 6 expression in colorectal cancer.
    BMC Cancer. 2019;19:429.
    PubMed     Abstract available

  145. LEE DW, Han SW, Cha Y, Bae JM, et al
    Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
    BMC Cancer. 2019;19:421.
    PubMed     Abstract available

  146. HINES RB, Jiban MJH, Specogna AV, Vishnubhotla P, et al
    The association between post-treatment surveillance testing and survival in stage II and III colon cancer patients: An observational comparative effectiveness study.
    BMC Cancer. 2019;19:418.
    PubMed     Abstract available

    April 2019
  147. LEE JL, Lim SB, Yu CS, Park IJ, et al
    Local excision in mid-to-low rectal cancer patients who revealed clinically total or near-total regression after preoperative chemoradiotherapy; a proposed trial.
    BMC Cancer. 2019;19:404.
    PubMed     Abstract available

  148. BUNDGAARD-NIELSEN C, Baandrup UT, Nielsen LP, Sorensen S, et al
    The presence of bacteria varies between colorectal adenocarcinomas, precursor lesions and non-malignant tissue.
    BMC Cancer. 2019;19:399.
    PubMed     Abstract available

  149. ROVERS KP, Bakkers C, Simkens GAAM, Burger JWA, et al
    Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, ra
    BMC Cancer. 2019;19:390.
    PubMed     Abstract available

  150. DULSKAS A, Cereska V, Zurauskas E, Stratilatovas E, et al
    Prostate cancer solitary metastasis to anal canal: case report and review of literature.
    BMC Cancer. 2019;19:374.
    PubMed     Abstract available

  151. DE MESQUITA GHA, Carvalho BJ, de Almeida Medeiros KA, Nii F, et al
    Intussusception reveals MUTYH-associated polyposis syndrome and colorectal cancer: a case report.
    BMC Cancer. 2019;19:324.
    PubMed     Abstract available

  152. BUISMAN FE, Homs MYV, Grunhagen DJ, Filipe WF, et al
    Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.
    BMC Cancer. 2019;19:327.
    PubMed     Abstract available

  153. WU YY, Zhang X, Qin YY, Qin JQ, et al
    Mean platelet volume/platelet count ratio in colorectal cancer: a retrospective clinical study.
    BMC Cancer. 2019;19:314.
    PubMed     Abstract available

  154. ROTHE F, Maetens M, Rouas G, Paesmans M, et al
    CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.
    BMC Cancer. 2019;19:304.
    PubMed     Abstract available

  155. GARCIA-TORRECILLAS JM, Olvera-Porcel MC, Ferrer-Marquez M, Rubio-Gil F, et al
    Spatial and temporal variations in Spain in the standardised ratio of in-hospital mortality due to colorectal cancer, 2008-2014.
    BMC Cancer. 2019;19:310.
    PubMed     Abstract available

  156. KIM E, Jung S, Park WS, Lee JH, et al
    Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data.
    BMC Cancer. 2019;19:302.
    PubMed     Abstract available

    March 2019
  157. SANDBERG TP, Stuart MPME, Oosting J, Tollenaar RAEM, et al
    Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer.
    BMC Cancer. 2019;19:284.
    PubMed     Abstract available

  158. ZHENG B, Wang X, Wei M, Wang Q, et al
    First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:280.
    PubMed     Abstract available

  159. HARLE A, Guillet J, Thomas J, Demange J, et al
    HPV insertional pattern as a personalized tumor marker for the optimized tumor diagnosis and follow-up of patients with HPV-associated carcinomas: a case report.
    BMC Cancer. 2019;19:277.
    PubMed     Abstract available

  160. BOWLES EJA, Yu O, Ziebell R, Chen L, et al
    Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study.
    BMC Cancer. 2019;19:270.
    PubMed     Abstract available

  161. HARADA K, Okamoto W, Mimaki S, Kawamoto Y, et al
    Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
    BMC Cancer. 2019;19:255.
    PubMed     Abstract available

  162. BASTIAENEN VP, Klaver CEL, Kok NFM, de Wilt JHW, et al
    Second and third look laparoscopy in pT4 colon cancer patients for early detection of peritoneal metastases; the COLOPEC 2 randomized multicentre trial.
    BMC Cancer. 2019;19:254.
    PubMed     Abstract available

  163. SHIBUTANI M, Maeda K, Nagahara H, Fukuoka T, et al
    The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study.
    BMC Cancer. 2019;19:241.
    PubMed     Abstract available

  164. VAN BLARIGAN EL, Chan H, Van Loon K, Kenfield SA, et al
    Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors (Smart Pace): a pilot randomized controlled trial.
    BMC Cancer. 2019;19:218.
    PubMed     Abstract available

  165. KAZLAUSKAS A, Darinskas A, Meskys R, Tamasauskas A, et al
    Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
    BMC Cancer. 2019;19:197.
    PubMed     Abstract available

  166. HUMMEL S, Kohlmann W, Kollmeyer TM, Jenkins R, et al
    The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database.
    BMC Cancer. 2019;19:190.
    PubMed     Abstract available

    February 2019
  167. JI H, Lu L, Huang J, Liu Y, et al
    IL1A polymorphisms is a risk factor for colorectal cancer in Chinese Han population: a case control study.
    BMC Cancer. 2019;19:181.
    PubMed     Abstract available

  168. TANABE T, Shida D, Tsukamoto S, Morizono G, et al
    Metachronous metastasis to inguinal lymph nodes from sigmoid colon adenocarcinoma with abdominal wall metastasis: a case report.
    BMC Cancer. 2019;19:180.
    PubMed     Abstract available

  169. KLEMENT RJ, Abbasi-Senger N, Adebahr S, Alheid H, et al
    The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.
    BMC Cancer. 2019;19:173.
    PubMed     Abstract available

  170. WANG Y, Jiang T, Jiang M, Gu S, et al
    Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis.
    BMC Cancer. 2019;19:177.
    PubMed     Abstract available

  171. MJELLE R, Sjursen W, Thommesen L, Saetrom P, et al
    Small RNA expression from viruses, bacteria and human miRNAs in colon cancer tissue and its association with microsatellite instability and tumor location.
    BMC Cancer. 2019;19:161.
    PubMed     Abstract available

  172. CHEN M, Sharma A, Lin Y, Wu Y, et al
    Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells.
    BMC Cancer. 2019;19:153.
    PubMed     Abstract available

  173. KHAN OF, Cusano E, Raissouni S, Pabia M, et al
    Immediate-term cognitive impairment following intravenous (IV) chemotherapy: a prospective pre-post design study.
    BMC Cancer. 2019;19:150.
    PubMed     Abstract available

  174. ERIKSEN AC, Sorensen FB, Lindebjerg J, Hager H, et al
    Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort.
    BMC Cancer. 2019;19:142.
    PubMed     Abstract available

  175. CHARETTE N, Vandeputte C, Ameye L, Bogaert CV, et al
    Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.
    BMC Cancer. 2019;19:134.
    PubMed     Abstract available

  176. PENNEY ME, Parfrey PS, Savas S, Yilmaz YE, et al
    A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer.
    BMC Cancer. 2019;19:133.
    PubMed     Abstract available

  177. LUO ZW, Zhu MG, Zhang ZQ, Ye FJ, et al
    Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis.
    BMC Cancer. 2019;19:123.
    PubMed     Abstract available

  178. SCHUURHUIZEN CSEW, Braamse AMJ, Konings IRHM, Verheul HMW, et al
    Predictors for use of psychosocial services in patients with metastatic colorectal cancer receiving first line systemic treatment.
    BMC Cancer. 2019;19:115.
    PubMed     Abstract available

    January 2019
  179. VAN ROOIJEN S, Carli F, Dalton S, Thomas G, et al
    Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation.
    BMC Cancer. 2019;19:98.
    PubMed     Abstract available

  180. CASTELLANO-CASTILLO D, Morcillo S, Crujeiras AB, Sanchez-Alcoholado L, et al
    Association between serum 25-hydroxyvitamin D and global DNA methylation in visceral adipose tissue from colorectal cancer patients.
    BMC Cancer. 2019;19:93.
    PubMed     Abstract available

  181. LI B, Wang Y, Yin L, Huang G, et al
    Glucocorticoids promote the development of azoxymethane and dextran sulfate sodium-induced colorectal carcinoma in mice.
    BMC Cancer. 2019;19:94.
    PubMed     Abstract available

  182. CAI SR, Huang YQ, Zhang SZ, Li QL, et al
    Effects of subitems in the colorectal cancer screening protocol on the Chinese colorectal cancer screening program: an analysis based on natural community screening results.
    BMC Cancer. 2019;19:47.
    PubMed     Abstract available

  183. XIN H, Wang C, Liu Z
    miR-196a-5p promotes metastasis of colorectal cancer via targeting IkappaBalpha.
    BMC Cancer. 2019;19:30.
    PubMed     Abstract available

  184. CHANG J, Lin G, Ye M, Tong D, et al
    Decreased mean platelet volume predicts poor prognosis in metastatic colorectal cancer patients treated with first-line chemotherapy: results from mCRC biomarker study.
    BMC Cancer. 2019;19:15.
    PubMed     Abstract available

    December 2018
  185. TIAN P, Zhu Y, Zhang C, Guo X, et al
    Ras-ERK1/2 signaling contributes to the development of colorectal cancer via regulating H3K9ac.
    BMC Cancer. 2018;18:1286.
    PubMed     Abstract available

  186. XU Y, Yang X, Gao D, Yang L, et al
    Dihomo-gamma-linolenic acid inhibits xenograft tumor growth in mice bearing shRNA-transfected HCA-7 cells targeting delta-5-desaturase.
    BMC Cancer. 2018;18:1268.
    PubMed     Abstract available

  187. BARRESI V, Cinnirella G, Valenti G, Spampinato G, et al
    Gene expression profiles in genome instability-based classes of colorectal cancer.
    BMC Cancer. 2018;18:1265.
    PubMed     Abstract available

  188. LIN Z, Liu J, Peng L, Zhang D, et al
    Complete pathological response following neoadjuvant FOLFOX chemotherapy in BRCA2-mutant locally advanced rectal cancer: a case report.
    BMC Cancer. 2018;18:1253.
    PubMed     Abstract available

  189. LIU M, Sun W, Cai YY, Wu HZ, et al
    Validation of Quality of Life Instruments for Cancer Patients - Colorectal Cancer (QLICP-CR) in patients with colorectal cancer in Northeast China.
    BMC Cancer. 2018;18:1228.
    PubMed     Abstract available

  190. ALSHERIDAH N, Akhtar S
    Diet, obesity and colorectal carcinoma risk: results from a national cancer registry-based middle-eastern study.
    BMC Cancer. 2018;18:1227.
    PubMed     Abstract available

  191. DEN BAKKER CM, Schaafsma FG, Huirne JAF, Consten ECJ, et al
    Cancer survivors' needs during various treatment phases after multimodal treatment for colon cancer - is there a role for eHealth?
    BMC Cancer. 2018;18:1207.
    PubMed     Abstract available

  192. OYEYEMI SO, Braaten T, Licaj I, Lund E, et al
    Physical activity patterns and the risk of colorectal cancer in the Norwegian Women and Cancer study: a population-based prospective study.
    BMC Cancer. 2018;18:1216.
    PubMed     Abstract available

  193. PETRERA M, Paleari L, Clavarezza M, Puntoni M, et al
    The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 x 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.
    BMC Cancer. 2018;18:1210.
    PubMed     Abstract available

  194. FORTEA-SANCHIS C, Martinez-Ramos D, Escrig-Sos J
    The lymph node status as a prognostic factor in colon cancer: comparative population study of classifications using the logarithm of the ratio between metastatic and nonmetastatic nodes (LODDS) versus the pN-TNM classification and ganglion ratio syste
    BMC Cancer. 2018;18:1208.
    PubMed     Abstract available

  195. JANG M, Kwon Y, Kim H, Kim H, et al
    Microsatellite instability test using peptide nucleic acid probe-mediated melting point analysis: a comparison study.
    BMC Cancer. 2018;18:1218.
    PubMed     Abstract available

  196. DIMITRIOU N, Felekouras E, Karavokyros I, Alexandrou A, et al
    Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients.
    BMC Cancer. 2018;18:1202.
    PubMed     Abstract available

    November 2018
  197. POMPSCH M, Vogel J, Classen F, Kranz P, et al
    The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia.
    BMC Cancer. 2018;18:1190.
    PubMed     Abstract available

  198. RATJEN I, Schafmayer C, Enderle J, di Giuseppe R, et al
    Health-related quality of life in long-term survivors of colorectal cancer and its association with all-cause mortality: a German cohort study.
    BMC Cancer. 2018;18:1156.
    PubMed     Abstract available

  199. CHEN Y, Tan F, Wei L, Li X, et al
    Sleep duration and the risk of cancer: a systematic review and meta-analysis including dose-response relationship.
    BMC Cancer. 2018;18:1149.
    PubMed     Abstract available

  200. YAMAURA M, Yamada T, Watanabe R, Kawai H, et al
    Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report.
    BMC Cancer. 2018;18:1142.
    PubMed     Abstract available

  201. HU H, Huang J, Lan P, Wang L, et al
    CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial.
    BMC Cancer. 2018;18:1145.
    PubMed     Abstract available

  202. KASPER S, Kisro J, Fuchs M, Muller C, et al
    Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
    BMC Cancer. 2018;18:1124.
    PubMed     Abstract available

  203. SHARAF LK, Sharma M, Chandel D, Shukla G, et al
    Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis.
    BMC Cancer. 2018;18:1111.
    PubMed     Abstract available

  204. WANG F, He W, Jiang C, Guo G, et al
    Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer.
    BMC Cancer. 2018;18:1102.
    PubMed     Abstract available

  205. LIU FR, Bai S, Feng Q, Pan XY, et al
    Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells.
    BMC Cancer. 2018;18:1087.
    PubMed     Abstract available

  206. BELLUCO C, Forlin M, Delrio P, Rega D, et al
    Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
    BMC Cancer. 2018;18:1094.
    PubMed     Abstract available

  207. TIAN Y, Li J, Zhou T, Tong D, et al
    Spatially varying effects of predictors for the survival prediction of nonmetastatic colorectal Cancer.
    BMC Cancer. 2018;18:1084.
    PubMed     Abstract available

  208. YU P, Zhou M, Qu J, Fu L, et al
    The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients.
    BMC Cancer. 2018;18:1076.
    PubMed     Abstract available

  209. ASHKTORAB H, Rahi H, Nouraie M, Shokrani B, et al
    GPNMB methylation: a new marker of potentially carcinogenic colon lesions.
    BMC Cancer. 2018;18:1068.
    PubMed     Abstract available

  210. NAGATA N, Nishijima T, Niikura R, Yokoyama T, et al
    Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study.
    BMC Cancer. 2018;18:1066.
    PubMed     Abstract available

  211. MAHMOOD S, English DR, MacInnis RJ, Karahalios A, et al
    Domain-specific physical activity and the risk of colorectal cancer: results from the Melbourne Collaborative Cohort Study.
    BMC Cancer. 2018;18:1063.
    PubMed     Abstract available

  212. LEE CH, Im EJ, Moon PG, Baek MC, et al
    Discovery of a diagnostic biomarker for colon cancer through proteomic profiling of small extracellular vesicles.
    BMC Cancer. 2018;18:1058.
    PubMed     Abstract available

  213. CRUZ-NOVA P, Schnoor M, Correa-Basurto J, Bello M, et al
    The small organic molecule C19 binds and strengthens the KRAS4b-PDEdelta complex and inhibits growth of colorectal cancer cells in vitro and in vivo.
    BMC Cancer. 2018;18:1056.
    PubMed     Abstract available

    October 2018
  214. KAERLEV L, Iachina M, Trosko O, Qvist N, et al
    Colon cancer patients with a serious psychiatric disorder present with a more advanced cancer stage and receive less adjuvant chemotherapy - A Nationwide Danish Cohort Study.
    BMC Cancer. 2018;18:1050.
    PubMed     Abstract available

  215. YE X, Mo M, Xu S, Yang Q, et al
    The hypermethylation of p16 gene exon 1 and exon 2: potential biomarkers for colorectal cancer and are associated with cancer pathological staging.
    BMC Cancer. 2018;18:1023.
    PubMed     Abstract available

  216. O'GORMAN C, Stack J, O'Ceilleachair A, Denieffe S, et al
    Colorectal cancer survivors: an investigation of symptom burden and influencing factors.
    BMC Cancer. 2018;18:1022.
    PubMed     Abstract available

  217. ZENG Z, Yang H, Xiao S
    ACTL6A expression promotes invasion, metastasis and epithelial mesenchymal transition of colon cancer.
    BMC Cancer. 2018;18:1020.
    PubMed     Abstract available

  218. PERTTULA K, Schiffman C, Edmands WMB, Petrick L, et al
    Untargeted lipidomic features associated with colorectal cancer in a prospective cohort.
    BMC Cancer. 2018;18:996.
    PubMed     Abstract available

  219. SPERLICH A, Balmert A, Doll D, Bauer S, et al
    Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer.
    BMC Cancer. 2018;18:998.
    PubMed     Abstract available

  220. SHIGEMATSU Y, Inamura K, Yamamoto N, Mise Y, et al
    Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis.
    BMC Cancer. 2018;18:980.
    PubMed     Abstract available

  221. WANG X, Zamdborg L, Ye H, Grills IS, et al
    A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.
    BMC Cancer. 2018;18:962.
    PubMed     Abstract available

  222. SHI J, Fei J, Yi Q, Shen L, et al
    Treatment of colon cancer in a patient with systemic lupus erythematosus: a case report.
    BMC Cancer. 2018;18:961.
    PubMed     Abstract available

  223. DOTE S, Itakura S, Kamei K, Hira D, et al
    Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
    BMC Cancer. 2018;18:957.
    PubMed     Abstract available

  224. MIZOTA Y, Kanemitsu Y, Tsukamoto S, Shida D, et al
    ROK study-C (Rainbow of KIBOU study-colorectum): a colorectal cancer survivor cohort study on food, nutrition, physical activity, psychosocial factors and its influences on colorectal cancer recurrence, survival and quality of life in Japan.
    BMC Cancer. 2018;18:953.
    PubMed     Abstract available

  225. CANTERO-CID R, Casas-Martin J, Hernandez-Jimenez E, Cubillos-Zapata C, et al
    PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
    BMC Cancer. 2018;18:945.
    PubMed     Abstract available

    September 2018
  226. YANG L, Xiong Z, Xie QK, He W, et al
    Second primary colorectal cancer after the initial primary colorectal cancer.
    BMC Cancer. 2018;18:931.
    PubMed     Abstract available

  227. DOS SANTOS JS, Bonafe GA, Pereira JA, Kanno DT, et al
    Rare perianal extramammary Paget disease successfully treated using topical Imiquimod therapy.
    BMC Cancer. 2018;18:921.
    PubMed     Abstract available

  228. TIKK K, Czock D, Haefeli WE, Kopp-Schneider A, et al
    Clinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms.
    BMC Cancer. 2018;18:914.
    PubMed     Abstract available

  229. WHITE A, Ironmonger L, Steele RJC, Ormiston-Smith N, et al
    A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK.
    BMC Cancer. 2018;18:906.
    PubMed     Abstract available

  230. LI N, Zhou W, Zhao L, Zhou J, et al
    Endometriosis-associated recto-sigmoid cancer: a case report.
    BMC Cancer. 2018;18:905.
    PubMed     Abstract available

  231. SEIDENSTICKER R, Damm R, Enge J, Seidensticker M, et al
    Local ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival.
    BMC Cancer. 2018;18:882.
    PubMed     Abstract available

  232. SCHLIEMANN D, Donnelly M, Dahlui M, Loh SY, et al
    The 'Be Cancer Alert Campaign': protocol to evaluate a mass media campaign to raise awareness about breast and colorectal cancer in Malaysia.
    BMC Cancer. 2018;18:881.
    PubMed     Abstract available

  233. MENDEZ LC, Hsieh E, Earle CC, Wong S, et al
    Synchronous anal canal carcinoma in a heterosexual couple.
    BMC Cancer. 2018;18:884.
    PubMed     Abstract available

  234. HO V, Chung L, Singh A, Lea V, et al
    Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis.
    BMC Cancer. 2018;18:869.
    PubMed     Abstract available

    August 2018
  235. DURINIKOVA E, Kozovska Z, Poturnajova M, Plava J, et al
    ALDH1A3 upregulation and spontaneous metastasis formation is associated with acquired chemoresistance in colorectal cancer cells.
    BMC Cancer. 2018;18:848.
    PubMed     Abstract available

  236. LUALDI M, Cavalleri A, Battaglia L, Colombo A, et al
    Early detection of colorectal adenocarcinoma: a clinical decision support tool based on plasma porphyrin accumulation and risk factors.
    BMC Cancer. 2018;18:841.
    PubMed     Abstract available

  237. SUN X, Ju T, Cummings RD
    Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers.
    BMC Cancer. 2018;18:827.
    PubMed     Abstract available

  238. SABER MM, Al-Mahallawi AM, Nassar NN, Stork B, et al
    Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes.
    BMC Cancer. 2018;18:822.
    PubMed     Abstract available

  239. PUIJK RS, Ruarus AH, Vroomen LGPH, van Tilborg AAJM, et al
    Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial.
    BMC Cancer. 2018;18:821.
    PubMed     Abstract available

  240. RUDERMAN S, Eshein A, Valuckaite V, Dougherty U, et al
    Early increase in blood supply (EIBS) is associated with tumor risk in the Azoxymethane model of colon cancer.
    BMC Cancer. 2018;18:814.
    PubMed     Abstract available

  241. TOSI D, Perez-Gracia E, Atis S, Vie N, et al
    Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
    BMC Cancer. 2018;18:812.
    PubMed     Abstract available

  242. LAN L, Liu H, Smith AR, Appelman C, et al
    Natural product derivative Gossypolone inhibits Musashi family of RNA-binding proteins.
    BMC Cancer. 2018;18:809.
    PubMed     Abstract available

  243. REDMOND HP, Neary PM, Jinih M, O'Connell E, et al
    RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer - the S.U.R.G.U.V.A.N.T. trial.
    BMC Cancer. 2018;18:794.
    PubMed     Abstract available

  244. LI N, Chen M, Cao Y, Li H, et al
    Bcl-2-associated athanogene 3(BAG3) is associated with tumor cell proliferation, migration, invasion and chemoresistance in colorectal cancer.
    BMC Cancer. 2018;18:793.
    PubMed     Abstract available

  245. GOERE D, Pignon JP, Gelli M, Elias D, et al
    Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
    BMC Cancer. 2018;18:787.
    PubMed     Abstract available

  246. KORDOWSKI F, Kolarova J, Schafmayer C, Buch S, et al
    Aberrant DNA methylation of ADAMTS16 in colorectal and other epithelial cancers.
    BMC Cancer. 2018;18:796.
    PubMed     Abstract available

    July 2018
  247. CHIU KWH, Lam KO, An H, Cheung GTC, et al
    Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis.
    BMC Cancer. 2018;18:776.
    PubMed     Abstract available

  248. MOGENSEN MB, Rossing M, Ostrup O, Larsen PN, et al
    Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing.
    BMC Cancer. 2018;18:752.
    PubMed     Abstract available

  249. LEERMAKERS L, Doking S, Thewes B, Braamse AMJ, et al
    Study protocol of the CORRECT multicenter trial: the efficacy of blended cognitive behavioral therapy for reducing psychological distress in colorectal cancer survivors.
    BMC Cancer. 2018;18:748.
    PubMed     Abstract available

  250. TIKK K, Weigl K, Hoffmeister M, Igel S, et al
    Study protocol of the RaPS study: novel risk adapted prevention strategies for people with a family history of colorectal cancer.
    BMC Cancer. 2018;18:720.
    PubMed     Abstract available

    June 2018
  251. MOLNAR B, Galamb O, Peterfia B, Wichmann B, et al
    Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations.
    BMC Cancer. 2018;18:695.
    PubMed     Abstract available

  252. YOUNG EL, Thompson BA, Neklason DW, Firpo MA, et al
    Pancreatic cancer as a sentinel for hereditary cancer predisposition.
    BMC Cancer. 2018;18:697.
    PubMed     Abstract available

  253. CRESPO A, Garcia-Suarez O, Fernandez-Vega I, Solis-Hernandez MP, et al
    Heparan sulfate proteoglycans undergo differential expression alterations in left sided colorectal cancer, depending on their metastatic character.
    BMC Cancer. 2018;18:687.
    PubMed     Abstract available

  254. BOCKELMAN C, Beilmann-Lehtonen I, Kaprio T, Koskensalo S, et al
    Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.
    BMC Cancer. 2018;18:679.
    PubMed     Abstract available

  255. NEILSEN BK, Chakraborty B, McCall JL, Frodyma DE, et al
    WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage.
    BMC Cancer. 2018;18:673.
    PubMed     Abstract available

  256. KOZOVSKA Z, Patsalias A, Bajzik V, Durinikova E, et al
    ALDH1A inhibition sensitizes colon cancer cells to chemotherapy.
    BMC Cancer. 2018;18:656.
    PubMed     Abstract available

  257. PANATO C, Abusamaan K, Bidoli E, Hamdi-Cherif M, et al
    Survival after the diagnosis of breast or colorectal cancer in the GAZA Strip from 2005 to 2014.
    BMC Cancer. 2018;18:632.
    PubMed     Abstract available

  258. GUAN X, Wang Y, Hu H, Zhao Z, et al
    Reconsideration of the optimal minimum lymph node count for young colon cancer patients: a population-based study.
    BMC Cancer. 2018;18:623.
    PubMed     Abstract available

    May 2018
  259. VANIA L, Rebelo TM, Ferreira E, Weiss SFT, et al
    Knock-down of LRP/LR promotes apoptosis in early and late stage colorectal carcinoma cells via caspase activation.
    BMC Cancer. 2018;18:602.
    PubMed     Abstract available

  260. KIM SC, Shin YK, Kim YA, Jang SG, et al
    Identification of genes inducing resistance to ionizing radiation in human rectal cancer cell lines: re-sensitization of radio-resistant rectal cancer cells through down regulating NDRG1.
    BMC Cancer. 2018;18:594.
    PubMed     Abstract available

  261. GONG X, Chen Z, Han Q, Chen C, et al
    Sanguinarine triggers intrinsic apoptosis to suppress colorectal cancer growth through disassociation between STRAP and MELK.
    BMC Cancer. 2018;18:578.
    PubMed     Abstract available

  262. PRICOLO VE, Bonvini M, Abelli CF
    Patterns of care for anal cancer in the United States - a comparison between academic and community cancer centers.
    BMC Cancer. 2018;18:567.
    PubMed     Abstract available

  263. YANG L, Xiong Z, Xie Q, He W, et al
    Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer.
    BMC Cancer. 2018;18:558.
    PubMed     Abstract available

  264. DE-MASI A, Davis E, Cuming T, Chindawi N, et al
    The acceptability of high resolution anoscopy examination in patients attending a tertiary referral centre.
    BMC Cancer. 2018;18:554.
    PubMed     Abstract available

  265. SHULDINER J, Liu Y, Lofters A
    Incidence of breast and colorectal cancer among immigrants in Ontario, Canada: a retrospective cohort study from 2004-2014.
    BMC Cancer. 2018;18:537.
    PubMed     Abstract available

  266. KIM CW, Kang BM, Kim IY, Kim JY, et al
    Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    BMC Cancer. 2018;18:538.
    PubMed     Abstract available

  267. RUHL R, Rana S, Kelley K, Espinosa-Diez C, et al
    microRNA-451a regulates colorectal cancer proliferation in response to radiation.
    BMC Cancer. 2018;18:517.
    PubMed     Abstract available

  268. REYNOLDS LM, Bissett IP, Consedine NS
    Emotional predictors of bowel screening: the avoidance-promoting role of fear, embarrassment, and disgust.
    BMC Cancer. 2018;18:518.
    PubMed     Abstract available

  269. DI GIROLAMO C, Walters S, Benitez Majano S, Rachet B, et al
    Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013.
    BMC Cancer. 2018;18:492.
    PubMed     Abstract available

  270. LILES EG, Perrin N, Rosales AG, Smith DH, et al
    Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study.
    BMC Cancer. 2018;18:509.
    PubMed     Abstract available

    April 2018
  271. MEI Z, Shao YW, Lin P, Cai X, et al
    SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
    BMC Cancer. 2018;18:479.
    PubMed     Abstract available

  272. FORSTER I, Brockmann M, Schildgen O, Schildgen V, et al
    Microsatellite instability testing in colorectal cancer using the QiaXcel advanced platform.
    BMC Cancer. 2018;18:484.
    PubMed     Abstract available

  273. HEALY MA, Morris AM, Abrahamse P, Ward KC, et al
    The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program.
    BMC Cancer. 2018;18:481.
    PubMed     Abstract available

  274. ZICHI C, Tampellini M, Tucci M, Sonetto C, et al
    FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report.
    BMC Cancer. 2018;18:470.
    PubMed     Abstract available

  275. BRONZWAER MES, Greuter MJE, Bleijenberg AGC, IJspeert JEG, et al
    Impact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening.
    BMC Cancer. 2018;18:465.
    PubMed     Abstract available

  276. ARROSPIDE A, Idigoras I, Mar J, de Koning H, et al
    Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model.
    BMC Cancer. 2018;18:464.
    PubMed     Abstract available

  277. MUNKER S, Gerken M, Fest P, Ott C, et al
    Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects.
    BMC Cancer. 2018;18:455.
    PubMed     Abstract available

  278. MENG H, Li W, Boardman LA, Wang L, et al
    Loss of ZG16 is associated with molecular and clinicopathological phenotypes of colorectal cancer.
    BMC Cancer. 2018;18:433.
    PubMed     Abstract available

  279. FANG HJ, Shan SB, Zhou YH, Zhong LY, et al
    Diabetes mellitus and the risk of gastrointestinal cancer in women compared with men: a meta-analysis of cohort studies.
    BMC Cancer. 2018;18:422.
    PubMed     Abstract available

  280. GAUTHE M, Richard-Molard M, Rigault E, Buecher B, et al
    Prognostic value of serum CYFRA 21-1 1 in patients with anal canal squamous cell carcinoma treated with radio(chemo)therapy.
    BMC Cancer. 2018;18:417.
    PubMed     Abstract available

  281. SHINOZAKI E, Tanabe K, Akiyoshi T, Tsuchida T, et al
    Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker.
    BMC Cancer. 2018;18:406.
    PubMed     Abstract available

  282. SORIANO LC, Soriano-Gabarro M, Garcia Rodriguez LA
    Trends in the contemporary incidence of colorectal cancer and patient characteristics in the United Kingdom: a population-based cohort study using The Health Improvement Network.
    BMC Cancer. 2018;18:402.
    PubMed     Abstract available

  283. DA COSTA PLN, Wynne D, Fifis T, Nguyen L, et al
    The kallikrein-Kinin system modulates the progression of colorectal liver metastases in a mouse model.
    BMC Cancer. 2018;18:382.
    PubMed     Abstract available

  284. WANG H, Chen X, Liu H, Mou T, et al
    Laparoscopy-assisted colectomy as an Oncologically safe alternative for patients with stage T4 Colon Cancer: a propensity-matched cohort study.
    BMC Cancer. 2018;18:370.
    PubMed     Abstract available

  285. SHIBUTANI M, Maeda K, Nagahara H, Fukuoka T, et al
    A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study.
    BMC Cancer. 2018;18:371.
    PubMed     Abstract available

  286. SANDRA-PETRESCU F, Herrle F, Burkholder I, Kienle P, et al
    Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial.
    BMC Cancer. 2018;18:369.
    PubMed     Abstract available

  287. SHIN HY, Suh M, Choi KS, Hwang SH, et al
    Higher satisfaction with an alternative collection device for stool sampling in colorectal cancer screening with fecal immunochemical test: a cross-sectional study.
    BMC Cancer. 2018;18:365.
    PubMed     Abstract available

  288. SHEN MH, Chen LP, Ho TF, Shih YY, et al
    Validation of the Taiwan Chinese version of the EORTC QLQ-CR29 to assess quality of life in colorectal cancer patients.
    BMC Cancer. 2018;18:353.
    PubMed     Abstract available

    March 2018
  289. SHIDA D, Ahiko Y, Tanabe T, Yoshida T, et al
    Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan.
    BMC Cancer. 2018;18:334.
    PubMed     Abstract available

  290. HAMASHIMA C, Sano H
    Association between age factors and strategies for promoting participation in gastric and colorectal cancer screenings.
    BMC Cancer. 2018;18:345.
    PubMed     Abstract available

  291. YOUNG JM, Durcinoska I, DeLoyde K, Solomon MJ, et al
    Patterns of follow up and survivorship care for people with colorectal cancer in new South Wales, Australia: a population-based survey.
    BMC Cancer. 2018;18:339.
    PubMed     Abstract available

  292. HUANG EY, Chang JC, Chen HH, Hsu CY, et al
    Carcinoembryonic antigen as a marker of radioresistance in colorectal cancer: a potential role of macrophages.
    BMC Cancer. 2018;18:321.
    PubMed     Abstract available

  293. BUROCK S, Daum S, Keilholz U, Neumann K, et al
    Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.
    BMC Cancer. 2018;18:297.
    PubMed     Abstract available

  294. TAI LH, Ananth AA, Seth R, Alkayyal A, et al
    Sepsis increases perioperative metastases in a murine model.
    BMC Cancer. 2018;18:277.
    PubMed     Abstract available

  295. GAO P, Huang XZ, Song YX, Sun JX, et al
    Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study.
    BMC Cancer. 2018;18:234.
    PubMed     Abstract available

  296. EL KINANY K, Deoula M, Hatime Z, Bennani B, et al
    Dairy products and colorectal cancer in middle eastern and north African countries: a systematic review.
    BMC Cancer. 2018;18:233.
    PubMed     Abstract available

    February 2018
  297. GRAY RT, Coleman HG, Hughes C, Murray LJ, et al
    Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study.
    BMC Cancer. 2018;18:228.
    PubMed     Abstract available

  298. STRAINIENE E, Binkis M, Urnikyte S, Stankevicius V, et al
    Microenvironment dependent gene expression signatures in reprogrammed human colon normal and cancer cell lines.
    BMC Cancer. 2018;18:222.
    PubMed     Abstract available

  299. KOWALCZYK M, Orlowski M, Siermontowski P, Mucha D, et al
    Occurrence of colorectal aberrant crypt foci depending on age and dietary patterns of patients.
    BMC Cancer. 2018;18:213.
    PubMed     Abstract available

  300. WANG T, Ning K, Sun X, Zhang C, et al
    Glycolysis is essential for chemoresistance induced by transient receptor potential channel C5 in colorectal cancer.
    BMC Cancer. 2018;18:207.
    PubMed     Abstract available

  301. HEUBLEIN S, Albertsmeier M, Pfeifer D, Loehrs L, et al
    Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer.
    BMC Cancer. 2018;18:201.
    PubMed     Abstract available

  302. ARJONA-SANCHEZ A, Barrios P, Boldo-Roda E, Camps B, et al
    HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma.
    BMC Cancer. 2018;18:183.
    PubMed     Abstract available

  303. ZHU Y, Wang PP, Zhai G, Bapat B, et al
    Association of rs2282679 A>C polymorphism in vitamin D binding protein gene with colorectal cancer risk and survival: effect modification by dietary vitamin D intake.
    BMC Cancer. 2018;18:155.
    PubMed     Abstract available

  304. RICHTER J, Kretz AL, Lemke J, Fauler M, et al
    CK1alpha overexpression correlates with poor survival in colorectal cancer.
    BMC Cancer. 2018;18:140.
    PubMed     Abstract available

  305. MARTINEZ-USEROS J, Moreno I, Fernandez-Acenero MJ, Rodriguez-Remirez M, et al
    The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
    BMC Cancer. 2018;18:144.
    PubMed     Abstract available

  306. KLAUCK PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, et al
    Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
    BMC Cancer. 2018;18:136.
    PubMed     Abstract available

  307. OZAKI Y, Shindoh J, Gonoi W, Nishioka Y, et al
    Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
    BMC Cancer. 2018;18:138.
    PubMed     Abstract available

    January 2018
  308. BATTAGLIN F, Schirripa M, Buggin F, Pietrantonio F, et al
    The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.
    BMC Cancer. 2018;18:98.
    PubMed     Abstract available

  309. BUSCH EL, Don PK, Chu H, Richardson DB, et al
    Diagnostic accuracy and prediction increment of markers of epithelial-mesenchymal transition to assess cancer cell detachment from primary tumors.
    BMC Cancer. 2018;18:82.
    PubMed     Abstract available

  310. ENGSTRAND J, Nilsson H, Stromberg C, Jonas E, et al
    Colorectal cancer liver metastases - a population-based study on incidence, management and survival.
    BMC Cancer. 2018;18:78.
    PubMed     Abstract available

  311. WANG X, Chen J, Wang J, Yu F, et al
    Correction to: Metalloproteases meprin-a (MEP1A) is a prognostic biomarker and promotes proliferation and invasion of colorectal cancer.
    BMC Cancer. 2018;18:70.
    PubMed     Abstract available

  312. SHAW E, Farris MS, Stone CR, Derksen JWG, et al
    Effects of physical activity on colorectal cancer risk among family history and body mass index subgroups: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:71.
    PubMed     Abstract available

  313. KONG X, Li J, Cai Y, Tian Y, et al
    A modified TNM staging system for non-metastatic colorectal cancer based on nomogram analysis of SEER database.
    BMC Cancer. 2018;18:50.
    PubMed     Abstract available

  314. DAVIS MM, Freeman M, Shannon J, Coronado GD, et al
    A systematic review of clinic and community intervention to increase fecal testing for colorectal cancer in rural and low-income populations in the United States - How, what and when?
    BMC Cancer. 2018;18:40.
    PubMed     Abstract available

  315. HERNANDEZ RK, Wade SW, Reich A, Pirolli M, et al
    Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
    BMC Cancer. 2018;18:44.
    PubMed     Abstract available

  316. GU MJ, Huang QC, Bao CZ, Li YJ, et al
    Attributable causes of colorectal cancer in China.
    BMC Cancer. 2018;18:38.
    PubMed     Abstract available

  317. FENNELL LJ, Jamieson S, McKeone D, Corish T, et al
    MLH1-93 G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAF(V600E) mutation.
    BMC Cancer. 2018;18:35.
    PubMed     Abstract available

  318. DEPCZYNSKI J, Dobbins T, Armstrong B, Lower T, et al
    Comparison of cancer incidence in Australian farm residents 45 years and over, compared to rural non-farm and urban residents - a data linkage study.
    BMC Cancer. 2018;18:33.
    PubMed     Abstract available

  319. FARSHIDFAR F, Kopciuk KA, Hilsden R, McGregor SE, et al
    A quantitative multimodal metabolomic assay for colorectal cancer.
    BMC Cancer. 2018;18:26.
    PubMed     Abstract available

  320. ARAKAWA K, Hata K, Yamamoto Y, Nishikawa T, et al
    Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum, prostate, and external ear canal-without microsatellite instability: a case report.
    BMC Cancer. 2018;18:24.
    PubMed     Abstract available

  321. HUEMER F, Thaler J, Piringer G, Hackl H, et al
    Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentose Tumortherapie).
    BMC Cancer. 2018;18:11.
    PubMed     Abstract available

    December 2017
  322. ZHANG K, Wang Y, Yu X, Shi Y, et al
    Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth.
    BMC Cancer. 2017;17:899.
    PubMed     Abstract available

  323. FALKOWSKI S, Woillard JB, Postil D, Tubiana-Mathieu N, et al
    Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study.
    BMC Cancer. 2017;17:901.
    PubMed     Abstract available

  324. SONG N, Shin A, Jung HS, Oh JH, et al
    Effects of interactions between common genetic variants and smoking on colorectal cancer.
    BMC Cancer. 2017;17:869.
    PubMed     Abstract available

  325. SHIN HY, Suh M, Park B, Jun JK, et al
    Perceptions of colorectal cancer screening and recommendation behaviors among physicians in Korea.
    BMC Cancer. 2017;17:860.
    PubMed     Abstract available

  326. YEH YS, Chang YT, Ma CJ, Huang CW, et al
    First-decade patient with colorectal cancer carrying both germline and somatic mutations in APC gene.
    BMC Cancer. 2017;17:849.
    PubMed     Abstract available

  327. CAO B, Luo L, Feng L, Ma S, et al
    A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
    BMC Cancer. 2017;17:844.
    PubMed     Abstract available

  328. BEEBE-DIMMER JL, Yee C, Paskett E, Schwartz AG, et al
    Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women's health initiative.
    BMC Cancer. 2017;17:848.
    PubMed     Abstract available

  329. LEE J, Xiao YY, Sun YY, Balderacchi J, et al
    Prevalence and characteristics of hereditary non-polyposis colorectal cancer (HNPCC) syndrome in immigrant Asian colorectal cancer patients.
    BMC Cancer. 2017;17:843.
    PubMed     Abstract available

  330. VULCAN A, Manjer J, Ohlsson B
    High blood glucose levels are associated with higher risk of colon cancer in men: a cohort study.
    BMC Cancer. 2017;17:842.
    PubMed     Abstract available

  331. COELHO H, Jones-Hughes T, Snowsill T, Briscoe S, et al
    A systematic review of test accuracy studies evaluating molecular micro-satellite instability testing for the detection of individuals with lynch syndrome.
    BMC Cancer. 2017;17:836.
    PubMed     Abstract available

  332. BENEDICTO A, Marquez J, Herrero A, Olaso E, et al
    Decreased expression of the beta2 integrin on tumor cells is associated with a reduction in liver metastasis of colorectal cancer in mice.
    BMC Cancer. 2017;17:827.
    PubMed     Abstract available

  333. ZHOU P, Wang C, Hu Z, Chen W, et al
    Genistein induces apoptosis of colon cancer cells by reversal of epithelial-to-mesenchymal via a Notch1/NF-kappaB/slug/E-cadherin pathway.
    BMC Cancer. 2017;17:813.
    PubMed     Abstract available

    November 2017
  334. HAN VAN KRIEKEN J, Kafatos G, Bennett J, Mineur L, et al
    Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.
    BMC Cancer. 2017;17:798.
    PubMed     Abstract available

  335. YANG J, Du XL, Li S, Wu Y, et al
    The risk and survival outcome of subsequent primary colorectal cancer after the first primary colorectal cancer: cases from 1973 to 2012.
    BMC Cancer. 2017;17:783.
    PubMed     Abstract available

  336. THIEBAULT Q, Defossez G, Karayan-Tapon L, Ingrand P, et al
    Analysis of factors influencing molecular testing at diagnostic of colorectal cancer.
    BMC Cancer. 2017;17:765.
    PubMed     Abstract available

  337. STEVANATO FILHO PR, Aguiar Junior S, Begnami MD, Kuasne H, et al
    Oestrogen receptor beta isoform expression in sporadic colorectal cancer, familial adenomatous polyposis and progressive stages of colorectal cancer.
    BMC Cancer. 2017;17:754.
    PubMed     Abstract available

  338. SONG Y, Yang Y, Gao P, Chen X, et al
    The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer.
    BMC Cancer. 2017;17:744.
    PubMed     Abstract available

  339. ALONSO-MOLERO J, Gonzalez-Donquiles C, Fernandez-Villa T, de Souza-Teixeira F, et al
    Alterations in PGC1alpha expression levels are involved in colorectal cancer risk: a qualitative systematic review.
    BMC Cancer. 2017;17:731.
    PubMed     Abstract available

  340. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Abstract available

  341. TAKAHASHI H, Takahashi M, Ohnuma S, Unno M, et al
    microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.
    BMC Cancer. 2017;17:723.
    PubMed     Abstract available

  342. YANG C, Zou K, Zheng L, Xiong B, et al
    Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
    BMC Cancer. 2017;17:725.
    PubMed     Abstract available

  343. YU X, Mi L, Dong J, Zou J, et al
    Long intergenic non-protein-coding RNA 1567 (LINC01567) acts as a "sponge" against microRNA-93 in regulating the proliferation and tumorigenesis of human colon cancer stem cells.
    BMC Cancer. 2017;17:716.
    PubMed     Abstract available

    October 2017
  344. STEVENS JR, Herrick JS, Wolff RK, Slattery ML, et al
    Identifying factors associated with the direction and significance of microRNA tumor-normal expression differences in colorectal cancer.
    BMC Cancer. 2017;17:707.
    PubMed     Abstract available

  345. RATJEN I, Schafmayer C, di Giuseppe R, Waniek S, et al
    Postdiagnostic physical activity, sleep duration, and TV watching and all-cause mortality among long-term colorectal cancer survivors: a prospective cohort study.
    BMC Cancer. 2017;17:701.
    PubMed     Abstract available

  346. UNGARI AQ, Pereira LRL, Nunes AA, Peria FM, et al
    Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school.
    BMC Cancer. 2017;17:691.
    PubMed     Abstract available

    August 2017
  347. PARK SM, Lee J, Kim YA, Chang YJ, et al
    Factors related with colorectal and stomach cancer screening practice among disease-free lung cancer survivors in Korea.
    BMC Cancer. 2017;17:600.
    PubMed     Abstract available

    June 2017
  348. COEN M, Rigamonti F, Roth A, Koessler T, et al
    Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature.
    BMC Cancer. 2017;17:394.
    PubMed     Abstract available

    May 2017
  349. DARWANTO A, Hein AM, Strauss S, Kong Y, et al
    Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform.
    BMC Cancer. 2017;17:358.
    PubMed     Abstract available

  350. DE FELICE F, Benevento I, Magnante AL, Musio D, et al
    Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer.
    BMC Cancer. 2017;17:325.
    PubMed     Abstract available

    April 2017
  351. LELONG B, de Chaisemartin C, Meillat H, Cournier S, et al
    A multicentre randomised controlled trial to evaluate the efficacy, morbidity and functional outcome of endoscopic transanal proctectomy versus laparoscopic proctectomy for low-lying rectal cancer (ETAP-GRECCAR 11 TRIAL): rationale and design.
    BMC Cancer. 2017;17:253.
    PubMed     Abstract available

    March 2017
  352. LI X, Lu H, Xu K, Wang H, et al
    Negative lymph node count is an independent prognostic factor for patients with rectal cancer who received preoperative radiotherapy.
    BMC Cancer. 2017;17:227.
    PubMed     Abstract available

  353. BERNTSEN S, Aaronson NK, Buffart L, Borjeson S, et al
    Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.
    BMC Cancer. 2017;17:218.
    PubMed     Abstract available

  354. CERVANTES-MADRID D, Wettergren Y, Falk P, Lundholm K, et al
    DNA alterations in Cd133+ and Cd133- tumour cells enriched from intra-operative human colon tumour biopsies.
    BMC Cancer. 2017;17:219.
    PubMed     Abstract available

  355. FENG YR, Jin J, Ren H, Wang X, et al
    Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.
    BMC Cancer. 2017;17:182.
    PubMed     Abstract available

  356. FORZATI F, De Martino M, Esposito F, Sepe R, et al
    miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene.
    BMC Cancer. 2017;17:170.
    PubMed     Abstract available

    February 2017
  357. BRUNET J, Burke S, Grocott MP, West MA, et al
    The effects of exercise on pain, fatigue, insomnia, and health perceptions in patients with operable advanced stage rectal cancer prior to surgery: a pilot trial.
    BMC Cancer. 2017;17:153.
    PubMed     Abstract available

  358. SINGH VP, Katta S, Kumar S
    WD-repeat protein WDR13 is a novel transcriptional regulator of c-Jun and modulates intestinal homeostasis in mice.
    BMC Cancer. 2017;17:148.
    PubMed     Abstract available

  359. WEYN C, Van Raemdonck S, Dendooven R, Maes V, et al
    Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.
    BMC Cancer. 2017;17:139.
    PubMed     Abstract available

  360. PAHLE J, Menzel L, Niesler N, Kobelt D, et al
    Rapid eradication of colon carcinoma by Clostridium perfringens Enterotoxin suicidal gene therapy.
    BMC Cancer. 2017;17:129.
    PubMed     Abstract available

  361. MEDENWALD D, Vordermark D, Dietzel CT
    Cancer mortality in former East and West Germany: a story of unification?
    BMC Cancer. 2017;17:94.
    PubMed     Abstract available

    January 2017
  362. STEVENSON HL, Prats MM, Sasatomi E
    Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
    BMC Cancer. 2017;17:35.
    PubMed     Abstract available

    December 2016
  363. YEDID N, Kalma Y, Malcov M, Amit A, et al
    The effect of a germline mutation in the APC gene on beta-catenin in human embryonic stem cells.
    BMC Cancer. 2016;16:952.
    PubMed     Abstract available

    November 2016
  364. ZHANG J, Ren J, Wei J, Chong CC, et al
    Alternative splicing of estrogen receptor alpha in hepatocellular carcinoma.
    BMC Cancer. 2016;16:926.
    PubMed     Abstract available

  365. STEPPELER C, Sodring M, Paulsen JE
    Colorectal Carcinogenesis in the A/J Min/+ Mouse Model is Inhibited by Hemin, Independently of Dietary Fat Content and Fecal Lipid Peroxidation Rate.
    BMC Cancer. 2016;16:832.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.